Warning: mysqli_query(): (HY000/1030): Got error 28 from storage engine in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
EPS for Acceleron Pharma Inc. (XLRN) Expected At $-0.67 - Money Making Articles Hot Stuff

EPS for Acceleron Pharma Inc. (XLRN) Expected At $-0.67

October 13, 2018 - By Clifton Ray

Acceleron Pharma Inc. (NASDAQ:XLRN) LogoInvestors sentiment increased to 1.47 in Q2 2018. Its up 0.20, from 1.27 in 2018Q1. It improved, as 17 investors sold Acceleron Pharma Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 38.98 million shares or 1.76% more from 38.30 million shares in 2018Q1 were reported.
Nj State Employees Deferred Compensation Plan stated it has 7,000 shares or 0.06% of all its holdings. Winslow Evans And Crocker Incorporated, a Massachusetts-based fund reported 1,616 shares. Franklin has invested 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN). Blackrock Incorporated owns 4.21 million shares for 0.01% of their portfolio. Metropolitan Life Insur New York holds 0% or 12,234 shares in its portfolio. Manufacturers Life The reported 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). 5,645 were reported by Parametrica Mgmt Ltd. 170,766 were reported by Tekla Cap Mngmt Limited Com. The New York-based Art Ltd Llc has invested 0.09% in Acceleron Pharma Inc. (NASDAQ:XLRN). C Grp A S has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 4,537 shares. Jasper Ridge Prns Ltd Partnership holds 0.05% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 12,498 shares. Axa reported 130,055 shares or 0.02% of all its holdings. Mackay Shields Lc invested in 0.01% or 17,483 shares. Captrust Fincl holds 3 shares or 0% of its portfolio. Deutsche Bank & Trust Ag stated it has 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN).

Since June 29, 2018, it had 0 insider buys, and 2 selling transactions for $1.88 million activity.

Analysts expect Acceleron Pharma Inc. (NASDAQ:XLRN) to report $-0.67 EPS on November, 6.They anticipate $0.02 EPS change or 3.08 % from last quarter’s $-0.65 EPS. After having $-0.63 EPS previously, Acceleron Pharma Inc.’s analysts see 6.35 % EPS growth. The stock increased 2.83% or $1.37 during the last trading session, reaching $49.86. About 236,518 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 31.27% since October 14, 2017 and is uptrending. It has outperformed by 15.65% the S&P500.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 5 analysts covering Acceleron Pharma (NASDAQ:XLRN), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Acceleron Pharma had 7 analyst reports since May 22, 2018 according to SRatingsIntel. Oppenheimer initiated the shares of XLRN in report on Tuesday, May 22 with “Hold” rating. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, September 10. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Neutral” rating given on Friday, June 29 by Goldman Sachs. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Neutral” rating by PiperJaffray on Tuesday, July 10. PiperJaffray upgraded the shares of XLRN in report on Tuesday, September 18 to “Overweight” rating. Credit Suisse maintained Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Friday, June 29. Credit Suisse has “Outperform” rating and $60 target. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, July 13.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $2.29 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The company's therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

More recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on September 28, 2018. Also Benzinga.com published the news titled: “Analyst: Acceleron’s Blood Disorder Candidate Luspatercept Has Blockbuster Potential” on September 18, 2018. Fool.com‘s news article titled: “3 Top Small-Cap Stocks to Buy Right Now” with publication date: October 04, 2018 was also an interesting one.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:



Warning: mysqli_query(): (HY000/1030): Got error 28 from storage engine in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
>